We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?
- Authors
Gazzah, Anas; Gonzales, Daniel Barrios; Levy, Antonin; Bahleda, Rastislav; Ducreux, Michel; Lacroix, Ludovic; Soria, Jean Charles
- Abstract
Despite a modern validated regimen of chemotherapy, advanced pancreatic adenocarcinoma remains the fourth most common cause of cancer-related death worldwide. The phosphoinositide 3-kinase pathway (PI3K)/Akt/mammalian target of rapamycin (mTOR) is a major signaling pathway that may be activated in advanced pancreatic cancer. To highlight the potential interest of this targetable pathway in selected advanced pancreatic cancer patients, we report herein a patient with an activated PI3K mutation who was treated in a phase I trial evaluating a treatment combination including an mTOR inhibitor.
- Subjects
RAPAMYCIN; PHOSPHOINOSITIDES; IMMUNOSUPPRESSIVE agents; CANCER chemotherapy; ADENOCARCINOMA
- Publication
OncoTargets & Therapy, 2013, Vol 6, p95
- ISSN
1178-6930
- Publication type
Article
- DOI
10.2147/OTT.S38520